Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker

Claudia Pontillo, Zhen-Yu Zhang, Joost P. Schanstra, Lotte Jacobs, Petra Zuerbig, Lutgarde Thijs, Adela Ramirez-Torres, Hiddo J. L. Heerspink, Morten Lindhardt, Ronald Klein, Trevor Orchard, Massimo Porta, Rudolf W. Bilous, Nishi Charturvedi, Peter Rossing, Antonia Vlahou, Eva Schepers, Griet Glorieux, William Mullen, Christian DellesPeter Verhamme, Raymond Vanholder, Jan A. Staessen*, Harald Mischak, Joachim Jankowski

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

45 Citations (Web of Science)

Abstract

Introduction: CKD273 is a urinary biomarker, which in advanced chronic kidney disease predicts further deterioration. We investigated whether CKD273 can also predict a decline of estimated glomerular filtration rate (eGFR) to

Methods: In analyses of 2087 individuals from 6 cohorts (46.4% women; 73.5% with diabetes; mean age, 46.1 years; eGFR >= 60 ml/min per 1.73 m2, 100%; urinary albumin excretion rate [UAE] >= 20 mu g/min, 6.2%), we accounted for cohort, sex, age, mean arterial pressure, diabetes, and eGFR at baseline and expressed associations per 1-SD increment in urinary biomarkers.

Results: Over 5 (median) follow-up visits, eGFR decreased more with higher baseline CKD273 than UAE (1.64 vs. 0.82 ml/min per 1.73 m(2); P <0.0001). Over 4.6 years (median), 390 participants experienced a first renal endpoint (eGFR decrease by >= 10 to = 1.23; P = 1.20; P = 20 mu g/min) and CKD273 (>= 0.154) thresholds yielded sensitivities of 30% and 33% and specificities of 82% and 83% (P

Discussion: In conclusion, while accounting for baseline eGFR, albuminuria, and covariables, CKD273 adds to the prediction of stage 3 chronic kidney disease, at which point intervention remains an achievable therapeutic target.

Original languageEnglish
Pages (from-to)1066-1075
Number of pages10
JournalKidney International Reports
Volume2
Issue number6
DOIs
Publication statusPublished - Nov 2017

Keywords

  • biomarker
  • chronic kidney disease
  • clinical science
  • glomerular filtration rate
  • peptidomics
  • proteomics
  • GLOMERULAR-FILTRATION-RATE
  • PROGRESSION
  • FIBROSIS
  • TRIAL
  • RECLASSIFICATION
  • MICROALBUMINURIA
  • CANDESARTAN
  • RETINOPATHY
  • PREVENTION
  • FIBRINOGEN

Cite this